Sbir phase II: preclinical validation of an ocular antioxidant enhancing gene delivery vehicle for dry macular degeneration
Ended Cooperative Agreement Awarded Last action
- Award ID
- 2208096
- Recipient
-
Oculogenex Inc. UEI K6P8KFEVG5D5
- Awarding agency
-
National Science Foundation
- Obligated
- $1,199,722
Award facts
- Assistance listing
- 47.084 NSF Technology, Innovation, and Partnerships
- Completion date
- Originally
- Place of performance
- Torrance, CA 90502, USA
Award details come from USAspending.gov.
Description
- Abstract
- The broader impact/commercial potential of this small business innovation research (sbir) phase II project is to further develop and commercialize an ocular gene therapy to reverse the effects of dry age-related macular degeneration (AMD), a disease affecting over 11 million americans today and representing the leading cause of blindness in the elderly in the united states. The proposed treatment has the potential to preserve independence, economic stability, and quality of life of those affected by AMD and reduce US healthcare costs with just a single treatment. This small business innovation research (sbir) phase II project technical plan will optimize the formulation, dose, and route of administration of an investigational therapy in a large animal model. The project will first develop gene therapy formulations with various vehicles. The formulations? Efficiency in retinal tissues with an injection into the eye will be assessed with preliminary pharmacokinetic analyses. Toxicology studies will be performed to assess safety and efficacy of the novel formulation and the injection route at various doses over 3 months. Subsequently, the project will assess risk in manufacturing the gene delivery vehicles to ensure that high concentrations can be manufactured for future clinical use. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the foundation's intellectual merit and broader impacts review criteria.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $199,722 | |
| Amendment | $0 | |
| Original award | $1,000,000 |
Quick answers
Who received award 2208096?
2208096 was awarded to Oculogenex Inc. by National Science Foundation on May 1, 2022.
How much is award 2208096 worth?
$1,199,722 has been obligated on 2208096.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award